Brief: Pharnext FY operating loss widens to 13.4 million euros
April 26 (Reuters) - Pharnext SAS PHARN.PA :
* FY operating revenue EUR 4.4 million ($4.78 million) versus EUR 2.6 million year ago
* Cash and cash equivalents at end of 2016 were EUR 16.7 million versus EUR 3.1 million year
earlier
* FY operating loss EUR 13.4 million versus loss of EUR 8.6 million year ago
Source text for Eikon: ID:nBw7l8bnpa
Further company coverage: PHARN.PA
($1 = 0.9198 euros)
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development